EP1198592A4 - Oligonucleotide die 2-aminoadenin und 5-substituierte pyrimidine enthalten. - Google Patents

Oligonucleotide die 2-aminoadenin und 5-substituierte pyrimidine enthalten.

Info

Publication number
EP1198592A4
EP1198592A4 EP00947043A EP00947043A EP1198592A4 EP 1198592 A4 EP1198592 A4 EP 1198592A4 EP 00947043 A EP00947043 A EP 00947043A EP 00947043 A EP00947043 A EP 00947043A EP 1198592 A4 EP1198592 A4 EP 1198592A4
Authority
EP
European Patent Office
Prior art keywords
aminoadenine
substituted pyrimidines
oligonucleotides incorporating
oligonucleotides
incorporating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00947043A
Other languages
English (en)
French (fr)
Other versions
EP1198592A1 (de
Inventor
Muthiah Manoharan
Phillip Dan Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP1198592A1 publication Critical patent/EP1198592A1/de
Publication of EP1198592A4 publication Critical patent/EP1198592A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/333—Modified A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00947043A 1999-07-06 2000-07-05 Oligonucleotide die 2-aminoadenin und 5-substituierte pyrimidine enthalten. Withdrawn EP1198592A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34810699A 1999-07-06 1999-07-06
US348106 1999-07-06
PCT/US2000/018415 WO2001002608A1 (en) 1999-07-06 2000-07-05 Oligonucleotides incorporating both 2-aminoadenine and 5-substituted pyrimidines

Publications (2)

Publication Number Publication Date
EP1198592A1 EP1198592A1 (de) 2002-04-24
EP1198592A4 true EP1198592A4 (de) 2002-09-18

Family

ID=23366665

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00947043A Withdrawn EP1198592A4 (de) 1999-07-06 2000-07-05 Oligonucleotide die 2-aminoadenin und 5-substituierte pyrimidine enthalten.

Country Status (3)

Country Link
EP (1) EP1198592A4 (de)
AU (1) AU6071300A (de)
WO (1) WO2001002608A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822089B1 (en) * 2000-03-29 2004-11-23 Isis Pharmaceuticals, Inc. Preparation of deoxynucleosides
SI3611266T1 (sl) * 2005-08-23 2023-02-28 The Trustees Of The University Of Pennsylvania Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo
CN108586550A (zh) * 2018-06-14 2018-09-28 慎终（上海）生物科技有限公司 2-氟腺苷的合成工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431523A2 (de) * 1989-12-04 1991-06-12 Enzo Biochem, Inc. Modifizierte Nukleotidverbindungen
WO1994002501A1 (en) * 1992-07-23 1994-02-03 Isis Pharmaceuticals, Inc. Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
WO1998039353A1 (en) * 1997-03-03 1998-09-11 The Perkin-Elmer Corporation Improved chimeric oligonucleotide vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883082A (en) * 1990-08-14 1999-03-16 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
US5582986A (en) * 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
KR0157487B1 (ko) * 1992-03-16 1998-10-15 비. 린네 파샬 단백질 키나아제 c의 올리고뉴클레오티드 조절
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431523A2 (de) * 1989-12-04 1991-06-12 Enzo Biochem, Inc. Modifizierte Nukleotidverbindungen
WO1994002501A1 (en) * 1992-07-23 1994-02-03 Isis Pharmaceuticals, Inc. Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
WO1998039353A1 (en) * 1997-03-03 1998-09-11 The Perkin-Elmer Corporation Improved chimeric oligonucleotide vectors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0102608A1 *

Also Published As

Publication number Publication date
EP1198592A1 (de) 2002-04-24
AU6071300A (en) 2001-01-22
WO2001002608A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
HUP0203430A3 (en) Quinazolinones and their use
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
DE59902573D1 (en) Dihydropyrimidine
ZA200204390B (en) Caspase inhibitors and uses thereof.
GB2355044B (en) Hinge
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
TW399609U (en) Container assembly and container unit
IL139899A0 (en) Uracil compounds and use thereof
EP1210084A4 (de) Pyridomorphinane, thienomorphinane und deren verwendung
IL128193A0 (en) Rhamnosyl-transferase gene and uses thereof
GB9922870D0 (en) Three element cold storage area
IL146531A0 (en) 5-substituted arylpyrimidines
EP1198592A4 (de) Oligonucleotide die 2-aminoadenin und 5-substituierte pyrimidine enthalten.
IL145711A0 (en) Thrombospondin-2 and uses thereof
GB0021915D0 (en) Creating and managing E-receipts
GB9924794D0 (en) Personal viewstation
EP1139972A4 (de) Dihydropyrimidine und deren verwendungen
GB9929581D0 (en) Comjpositions and their use
HUP0105189A3 (en) Organoprotective solutions and their use
AU144458S (en) Construction element
GB9910664D0 (en) Cells and assay
GB9923626D0 (en) Novel porous element and use thereof
GB9916675D0 (en) Enigma-sip and enigma-cell
IL149638A0 (en) S-allylmercaptoglutathione and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020130;LT PAYMENT 20020130;LV PAYMENT 20020130;MK PAYMENT 20020130;RO PAYMENT 20020130;SI PAYMENT 20020130

A4 Supplementary search report drawn up and despatched

Effective date: 20020801

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7C 12P 19/34 B, 7C 07H 21/00 B, 7C 07H 21/02 B, 7C 07H 21/04 B, 7A 01N 43/04 B, 7A 61K 31/70 B

17Q First examination report despatched

Effective date: 20040921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

18D Application deemed to be withdrawn

Effective date: 20050202